Market News
Breaking market news and updates
August PCE Report: Headline Inflation at 3.4%, Below Forecasts; Core Holds at 3.0% as Spending Jumps 0.9%
August 2026 PCE data show headline inflation at 3.4% year-over-year, below the 3.7% forecast, while core PCE held at 3.0%, consumer spending jumped 0.9% and traders pushed back October rate-hike odds.
Hormel Foods to Acquire Brakebush Brothers for $1.055 Billion in Cash, Eyes Fiscal 2028 EPS Accretion
Hormel Foods has agreed to acquire value-added chicken supplier Brakebush Brothers for about $1.055 billion in cash, funded with cash on hand and long-term debt, with adjusted EPS accretion expected beginning fiscal 2028.
HPE Lands First Helios Order: Vultr Commits $1.2 Billion for AMD-Powered AI Racks
HPE said cloud provider Vultr placed a $1.2 billion order for AMD Helios AI Rack by HPE systems — what HPE calls its first order for the new rack-scale platform pairing AMD Instinct GPUs with HPE networking.
Boeing Wins Navy's F/A-XX Contract for Sixth-Generation Carrier Fighter in Deal Reported Above $20 Billion
Boeing has been selected by the U.S. Navy to build the F/A-XX sixth-generation carrier fighter, a deal CNBC reported as worth more than $20 billion, citing the defense departments. Northrop Grumman lost the award.
30-Year Treasury Yield Tops 5.6%, Highest Since 2002, as Long-End Selloff Weighs on Stocks
The 30-year Treasury yield topped 5.6% on Tuesday, its highest since June 2002, as fiscal deficit worries, energy costs and Fed-hike bets drove a long-end selloff that pressured stocks and bank shares.
Novo Nordisk Licenses Hengrui's Phase 1-Ready Once-Weekly Oral Obesity Candidate in Deal Worth Up to $2.6 Billion
Novo Nordisk has licensed Hengrui Pharma's Phase 1-ready HRS-1596, a GLP-1/GIP dual receptor agonist with potential for once-weekly oral dosing, in a deal worth up to $2.6 billion including $300 million upfront, according to the companies and Reuters.
Stock Market Today: Utilities Leads While S&P 500 Slips
Utilities led the session while the S&P 500 slips. See the validated market scorecard, sector performance, and what traders are watching next.
AstraZeneca to Take Rights Equal to ~12% of Summit Therapeutics in $2 Billion Preferred Stock Deal, Opens Ivonescimab-ADC Collaboration
AstraZeneca will invest $2 billion in newly issued Summit Therapeutics preferred stock for rights equal to about 12% of its common stock and launch an ivonescimab-ADC clinical collaboration, per company and analyst reporting.
Pentagon Awards Raytheon Up to $20.7 Billion to Nearly Double AMRAAM Production
The Pentagon awarded Raytheon, an RTX business, a five-year contract with two option years worth up to $20.7 billion to expand AMRAAM production, though Congress has not yet funded the full deal.
No Public Disclosure of Piper Sandler-Perella Weinberg Acquisition Talks, Despite Contrasting Advisory Profiles
A review of public disclosures on Piper Sandler and Perella Weinberg shows contrasting advisory profiles but no report or company statement describing acquisition talks.
uniQure Shares Fall 64% as AMT-130's 48-Month Huntington's Data Miss Statistical Significance on Key Composite Measure
uniQure shares fell 64% after 48-month AMT-130 data showed a 44% slowing on the cUHDRS with a p-value of 0.144, missing statistical significance versus an external control, per investorshub.advfn.com.
Anthropic's Confidential IPO Filing Shows $518 Billion in AI Infrastructure Commitments, Most Locked In
Anthropic's confidential IPO prospectus discloses at least $518 billion in AI infrastructure commitments across six partners, with roughly 80% structured as non-cancelable, according to Reuters and Financial Times reporting.
Stop watching.
Start winning.
50,000+ traders get our daily brief before the market opens.
You're subscribed!
Check your inbox.
Free. No spam. Unsubscribe anytime.
